Menu
Search
|

Menu

Close
X

Homology Medicines Inc FIXX.OQ (NASDAQ Stock Exchange Global Select Market)

20.40 USD
-0.60 (-2.86%)
As of Apr 20
chart
Previous Close 21.00
Open 21.05
Volume 32,169
3m Avg Volume --
Today’s High 21.34
Today’s Low 20.16
52 Week High 24.40
52 Week Low 16.12
Shares Outstanding (mil) 36.08
Market Capitalization (mil) 736.05
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue
No Data Available
FY
-
FY
-
FY
-
FY
-
EPS
No Data Available
FY
-
FY
-
FY
-
FY
-

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.60
Price to Sales (TTM)
vs sector
--
7.07
Price to Book (MRQ)
vs sector
--
5.13
Price to Cash Flow (TTM)
vs sector
--
25.52
Total Debt to Equity (MRQ)
vs sector
--
13.97
LT Debt to Equity (MRQ)
vs sector
--
11.31
Return on Investment (TTM)
vs sector
--
13.19
Return on Equity (TTM)
vs sector
--
15.00

EXECUTIVE LEADERSHIP

Arthur Tzianabos
President, Chief Executive Officer, Director, Since 2016
Salary: --
Bonus: --
Sam Rasty
Chief Operating Officer, Since
Salary: --
Bonus: --
Albert Seymour
Chief Scientific Officer, Since
Salary: --
Bonus: --
Steven Gillis
Director, Since
Salary: --
Bonus: --
Kush Parmar
Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

45 Wiggins Ave
BEDFORD   MA   01730-2314

Phone: +1857.3051825

Homology Medicines, Inc. is a genetic medicines company translating gene editing and gene therapy technology into treatments for patients with rare diseases. The Company is focused on developing a pipeline of new medicines that address and cure the underlying cause of monogenic diseases in the liver, central nervous system (CNS), bone marrow, lung and the eye. The Company’s lead product candidate, HMI-102 is a gene therapy for the treatment of phenylketonuria (PKU). Its PKU program is focused on adults using the gene therapy approach. The Company’s suite of 15 adeno-associated virus vectors (AAVHSCs) enables it to focus on a method of gene editing called gene correction. The Company’s diverse set of AAVHSCs allows it to precisely target, via a single intravenous injection, a wide range of disease-relevant tissues, including the liver, central nervous system, or CNS, bone marrow, lung, muscle and eye, across both modalities - gene editing and gene therapy.

SPONSORED STORIES